![]() |
Volumn 2, Issue 1, 2001, Pages 109-124
|
Current treatment for ovarian cancer
a
|
Author keywords
Adjuvant chemotherapy; Carboplatin; Cisplatin; Cytoreductive surgery; Ovarian cancer; Paclitaxel; Treatment
|
Indexed keywords
AMIFOSTINE;
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DNA;
DOCETAXEL;
DOXORUBICIN;
EPIRUBICIN;
ETOPOSIDE;
GEMCITABINE;
IFOSFAMIDE;
MELPHALAN;
PACLITAXEL;
TAMOXIFEN;
TOPOTECAN;
ABDOMINAL HYSTERECTOMY;
ADVANCED CANCER;
BONE MARROW SUPPRESSION;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PALLIATIVE THERAPY;
CANCER STAGING;
CANCER SURVIVAL;
CARDIOTOXICITY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DRUG RESPONSE;
DRUG SENSITIVITY;
EARLY CANCER;
FATIGUE;
FEMALE;
HEARING LOSS;
HUMAN;
LYMPHADENECTOMY;
NAUSEA AND VOMITING;
NEPHROTOXICITY;
NEUROTOXICITY;
OVARY CANCER;
PROGNOSIS;
REVIEW;
SALPINGOOOPHORECTOMY;
TUMOR RECURRENCE;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHEMOTHERAPY, ADJUVANT;
FEMALE;
HUMANS;
NEOPLASM STAGING;
OVARIAN NEOPLASMS;
PROGNOSIS;
SALVAGE THERAPY;
|
EID: 0035002586
PISSN: 14656566
EISSN: None
Source Type: Journal
DOI: 10.1517/14656566.2.1.109 Document Type: Review |
Times cited : (40)
|
References (76)
|